Abnormalities in the hypothalamicâ€"pituitaryâ€"adrenal axis (HPA) have been the most consistently demonstrated biological markers in depressive illness. Numerous other neuroendocrine disturbances have also been described, including blunted clonidine-induced growth hormone releaseand blunted fenfluramine-inducedprolactin release.Thesedisturbances are generally interpreted in terms of monoaminergic receptor dysfunction. The theory presented here suggests that chronic stress which activates the HPA will in certain susceptible people produce changes in central monoamines.The high level of glucocorticoid receptors on such central neurons is postulated as mediating the alterations. Thus monoamine abnormalities, rather than being a core aetiological feature of depression, are seen as secondary to HPA overdrive.
the release of corticotropin-releasing hormone (CRH) from the paraventricular nucleus into the portal venous circulation, which in turn brings about the release of adrenocorticotropin (ACTH) from the anterior pituitary (Dornhorst eta!, 1981) . Increases in circulating ACTH stimulate glucocorticoid release from the adrenal cortex. A wide variety of both psychological and physical stimuli envoke this stress response, which is essential for survival. Work on adrenalectomised animals indicates that stressors that the animal will normally survive may prove fatal in the absence of glucocorticoids (Jones et a!, 1982 ).
The precise manner in which glucocorticoids enable us to adapt to stress is far from understood. What is certainly clear is that many brain regions, not just the hypothalamus, are important targets for peripherally produced glucocorticoids (McEwen et a!, 1979) and that although high levels of glucocorticoids are essential as an acute reaction to stress, chronically increased glucocorticoid levels may have a significant negative effect on the functional activity of the brain (Rees, 1978) . The central actions of CRH on visceral organ activity are similar to those which are directly stress induced. In dogs, for instance, Brown et a! (1982) showed that CRH administered centrally elevates blood pressure and increases heart rate. Similar results have also been described in sheep (Scoggins eta!, 1984) and in rhesus monkeys (Kahn eta!, 1983). As well as changes in cardiovascular function CRH also produces metabolic, gastro-intestinal and immune system responses.
It brings about an increase in plasma glucose concentration and a decrease in insulin levels (Brown et a!, 1982) . At the same time there is a significant inhibition of solid-phase gastric emptying and small intestinal transit time (Williams et 
a!, 1987; Lenz, 1989). Irwin et a! (1988) have
shown that intracerebroventricular administration of CRH reduces splenic natural killer cell activity in rats.
Cortisol is the principal circulating glucocorticoid in man while corticosterone is the principal gluco corticoid in some other species, such as rats. It is secreted in response to a wide variety of stimuli and apart from its action on the central nervous system (CNS) it promotes lipolysis and gluconeogenesis, and decreases energy expensive metabolic processes (Bondy, 1985) . As mentioned above the release of cortisol is brought about by ACTH which is cleaved from the large prohormone, pro-opiomelanocortin (POMC) (Mains et a!, 1977; Nakanishi et a!, 1979). This prohormone also gives rise to fl-lipotropin and j3-endorphin (Eipper & Mains, 1980) . The release of cortisol is controlled by two important negative feedback mechanisms which are mediated via gluco corticoid receptors both within the brain and the anterior pituitary, a rate-sensitive fast feedback system and a delayed feedback system (Jones et a!, 1982) .
Glucocorticoid receptors
Our knowledge of the pharmacology and functioning of central glucocorticoid receptors rests largely on studies conducted on rodents. Two types of central adrenal steroid receptor have been described: type 1 366 DINAN are mineralocorticoid receptors (MR receptors), which were first described by McEwen et al (1979) ; and type 2 are glucocorticoid receptors (OR receptors). The type 1 receptors have a high affinity for corticosterone in the rat and are found in high concentrations in extrahypothalamic limbic neurons of the septo-hippocampal complex, whereas in the pituitary relatively low levels are found (Reul & De Kloet, 1986) . They also have a high affinity for aldosterone and have been described by Beaumont & Fanestil (1983) as mineralocorticoid-like receptors. Overall the type 1 receptor is thought to mediate tonic influences of corticosterone or cortisol.
Type 2 (OR receptors) resemble physiochemically the classical OR system in the periphery and have the highest affinity for synthetic glucocorticoids such as RU28362 and dexamethasone, with a lower afinity for binding naturally occurring glucocorticoids (Reul & De Kloet, 1986; Sutanto & De Kloet, 1987) . The highest concentrations of these receptors in the brain are found in the dentate gyrus, lateral septum, paraventricular nucleus and also cortical and thalamic regions (Reul & De Kleot, 1986) . Van Eekelen et al (1987) used a monoclonal antibody against the rat liver OR to examine the distribution of type 2 receptors. In the hippocampus they found strong reactivity in CAl and CA2 pyramidal cells. In the hypothalamus they found that the activity was highest in the parvocellular neurons of the paraventricular nucleus and in the brainstem nucleus tractus solitarius and nucleus locus coeruleus.
These findings are in keeping with the previous work of Fuxe et al (1985) , who used a monoclonal immunoglobulin lgO2a antibody to map OR immunoreactive neurons in the telencephalon and diencephalon.
More recently Reul et al (1989) used 32P-labelled cRNA probes directed against type 1 and type 2 receptor messenger RNA to examine the distribution of these receptors in the rat. Type 1 messenger RNA was found in highest concentrations in the hippocampus and type 2 receptors at their highest density in both the cerebellum and hippocampus. When animals were adrenalectomised there was instant up-regulation of type 2 receptors and a down regulation was induced by dexamethasone treatment.
Stress-related cortisol changes are mediated by the type 2 receptor, and this may be significant in terms of the pathophysiology of depression. The type 2 receptor becomes occupied with increasing plasma cortisol levels, due to stress or circadian variation.
At resting morning levels of plasma cortisol only around lOÂ°loof type 2 receptors are occupied. However, following stress a peak of cortisol type 2 receptors are occupied at 75%. Overall the type 2 receptors are located in cell groups which are implicated in the co-ordination of behavioural and endocrine responses to stressful stimuli. Several behavioural effects of glucocorticoids are attributed to their action on type 2 receptors including effects on sleep (Oillin et al, 1972) and food intake (Liebowitz & Roland, 1984) .
Disturbancesof HPA in depression
It has long been recognised that a significant number of patients with major depression hypersecrete cortisol (Sachar et al, 1973) . Cortisol values often remain elevated throughout the day with an absence of normal diurnal variation (Sachar et a!, 1973) . The most widely studied dynamic endocrine test in the history of biological psychiatry is the dexamethasone suppression test, applied to major depressive illness. Dexamethasone is a synthetic steroid and when given at night to healthy subjects suppresses cortisol levels for at least 24 hours. Bernard Carroll has popularised the use of the modified dexamethasone suppression test (DST) for the investigation of depression (Carroll, 1982) . His group, on the basis of large-scale investigations both of healthy subjects and of various patient populations, put forward guidelines for conducting the test, which increase its sensitivity and specificity in the diagnosis of DMSâ€"III major depression of melancholic subtype. The test consists of administering dexamethasone 1 mg at 23.00 h, followed by serum cortisol estimation at 16.00 h the following afternoon. Dexamethasone non-suppression is defined as a serum cortisol level in excess of 5 @tg/dl or 137 nmol/1 at 16.00 h. Although relatively sensitive in the diagnosis of melancholia its specificity has been called into question (Coppen et al, 1983) . Non-suppression is also found in a significant percentage of alcoholics and patients with anorexia nervosa (Oerner & Owirtsman, 1981) , in the absence of depression. Most studies agree that the DST tends to normalise with effective treatment. Carroll & Haskett (1985) reported on 102 patients who had an abnormal DST. At the time of discharge 34Â°lostill showed non suppression. Of these patients the majority had a poor clinical outcome. Nemeroff & Evans (1984) also found that continued non-suppression was associated with poorer clinical response and increased risk of relapse. For a comprehensive review of the DST see Evans & Oolden (1987) and American Psychiatric Association Task Force (1987) .
The release of ACTH in response to CRH infusion is also blunted in depression and this blunting may be due to a down-regulation of anterior pituitary CRH receptors (Holsboer et al, 1985; Oold eta!, 1988; Ur et al, 1992) .
In support of such a view is the finding of increased CRH levels in the cerebrospinal fluid of depressed subjects (Nemeroff et a!, 1988) . Such an increase might lead to receptor down-regulation.
Rupprecht et a!(1991) have examined the functional activity of type 2 receptors on the lymphocytes of depressed patients. They studied 18 patients with umpolar depression who fulfilled DSM-HI-R criteria. Both depressed patients and healthy subjects were treated with metyrapone which blocks 11-@9-hydroxylase activity, thus decreasing cortisol levels. In normal healthy controls such pre-treatment enhanced type 2 receptor binding due to an upregulation of the receptor which did not take place in the depressives. These data support the view that in depressive illness there is decreased glucocorticoid receptor plasticity. The fact that tricyclic antidepressants were demon strated as blocking the reuptake ofthese monoamines provides one of the cornerstones of the monoamine hypothesis of depressive illness. For a comprehensive review of the theory see Tnmble (1988) . Most monoamine theories of depression put forward the view that the core defect in depressive illness lies in monoamine systems, and that abnormalities in the HPA and in other endocrine axes are secondary to the abnormalities in these systems. However, work by Dc Kloet et a! (1982, 1986, 1987) When normal subjects are treated for two days with dexamethasone 9 mg daily, blunting of OHRH/GH responses is found. This raises the question as to whether or not this putative marker of depression is in fact secondary to increased cortisol levels. When NA mediated OH release was examined we found that patients who were dexamethasone non-suppressors were far more likely to show blunting of response than subjects who were suppressors, again supporting the view that this endocrine abnormality may be Together with disturbances in the HPA the two classic monoamine neurotransmitters, noradrenaline secondary to hypercortisolism (Dinan & Barry, 1990 Pyridostigmine is an acetylcholinesterase inhibitor which increases OH levels by enhancing acetylcholine neurotransmission and thus inhibiting the influence of somatostatin (SS). We have described enhanced OH release in response to pyridostigmine challenge in patients with depression (O'Keane et a! l992a). The finding is best explained by the fact that glucocorticoids enhance SS tone (Oiustina eta!, 1990) which is removed by acetylcholine, accounting for the augmented OH release. Baclofen-induced OH release via GABAB receptors is reported as blunted in depression, especially in those who show dexamethasone non-suppression (O'Flynn & Dinan, 1993) . As in the case of acetyicholine the OABAB abnormality seems linked to disturbance of the HPA.
Cushing'ssyndromeand depression
Cushing's syndrome is a family of disorders with varying aetiologies all of which are associated with the excess production of cortisol (Krieger, 1983) . As early as 1913 in an article published in The American Journal of Insanity, Cushing described the behavioural disturbances associated with the condition. Later on he described a patient who was â€oe¿ easily fatigued, unable to concentrate his mind on his work and had fits of unnatural irritability alternated with periods of depressionâ€• (Cushing, 1932) . Cushing was therefore clearly aware of the assocition of the condition with mood disturbance.
In a studyof 25 patientswithCushing'ssyndrome Trethowan & Cobb (1952) found that depressive symptoms were common, while more recently 80% of 29 patients were reported by Cohen (1980) as presenting depressive symptoms, most notably insomnia, tearfulness, irritability and somatic preoccupation. Using the present state examination Kelly et al (1980 Kelly et al ( , 1983 found a 50% prevalence of depression.
The biochemical basis of the depression precipitated by the endocrine disturbance has not been established, but there are reports that cortisol reduction, for example brought about by metyrapone (an 1li3-hydroxylase inhibitor), reduces depressive symptoms (Jeffcoate et al, 1979; Kramlinger eta!, 1985) . This provides support for the view that hypercortisolaemia is the major factor contributing to the emergence of affective symptoms. Interestingly, exogenous synthetic steroids also produce mood disturbance but this is more commonly of a euphoric rather than a depressive picture (Ling et a!, 1981) . Depressive symptoms are more likely to arise when high steroid dosage is suddenly withdrawn.
Glucocorticoids and antidepressants
It is generally assumed that standard antidepressants act by blocking the uptake of monoamines and consequently inducing receptor alterations (Carlsson, 1977) . However, they also exert an important influence on the glucocorticoid receptor. The effect of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain has been investigated (Kitayama et a!, 1988) . A significant up-regulation of such receptors was found on the noradrenergic locus coeruleus and the 5-HT containing neurons of the raphe nucleus. Such an up-regulation would result in increased negative feedback, thus decreasing the overall activity of the HPA. These findings have been replicated in an in situ hybridisation study (Brady et a!, 1991) by corticosteroneof serotonin-l receptor capacity in raphe hippocampal system. Neuroendocrinology, 42, 5 13â€"521.
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British Journal of Psychiatry, 156, 680â€"684. and also generalised to the newer selective serotonin reuptake inhibitors (Pepin et a!, 1989) . This action of antidepressants could account for their capacity to suppress HPA activity (Shimoda et a!, 1988 ) and may be of clinical importance.
The HPA and depression
It is now widely accepted that major depressive illness results from an interaction of constitutional vulnerability and exposure to significant life events.
The constitutional vulnerability in many cases may be genetically determined (Gershon, 1983) although non-genetic maladaptive cognitive coping mechanisms may also be important. Numerous epidemiological studies have demonstrated the importance of exposure to significant life events in the genesis of most cases of depression (Paykel et a!, 1969; Brown et a!, 1975) . Presumably such psychologically stressful life events induce activation of the HPA. With chronic stress, especially in a biologically predisposed individual, the activation of the HPA may have a damaging impact (Checkley, 1992) . With such a high con centration of glucocorticoid receptors centrally, alteration of functioning within the limbic brain regions and in monoaminergic tracts may be induced.
If this hypothesis is correct the changes in central monoaminergic pathways occur as a direct consequence of overactivation of the HPA and the associated hypercortisolism, induced by the life events. Such a view is different from traditional theories of depressive illness which assume that these abnormalities in central monoamines are primary and induce secondary endocrine dis turbance.
Several important questions are raised by the hypothesis. Are all currently described biological markers of depression (with the exception of HPA disturbance) secondary to high glucocorticoid levels? By altering glucocorticoid levels in healthy subjects and in depressives it should be possible to examine their impact on markers such as REM latency, platelet 5-HT uptake, platelet imipramine binding, etc. An examination of patients placed on long-term steroid therapy, for example those with chronic obstructive airways or rheumatoid disease, would enable a proper understanding of the impact of glucocorticoids on central neurotransmitter function. Can depression be treated, either acutely or prophylactically, by modulating glucocorticoid response? This might be achieved pharmacologically or by appropriate cognitive interventions aimed at modifying the subjects' stress response.
